San Diego, CA – December 1, 2008 - TargeGen has announced that an oral presentation of preliminary results from a multi-center, US-based clinical trial of TG101348 in myeloproliferative disease patients has been scheduled at the 2008 American Society of Hematology (ASH) Meeting.

Details of the presentation are as follows:

Title: A Phase I Study of TG101348, an Orally Bioavailable JAK2-Selective Inhibitor, in Patients with Myelofibrosis
Presenter: Dr. Animesh Pardanani, Mayo Clinic
Session Name: Myeloproliferative Disorders-Experimental Therapeutics
Session Date: Sunday, December 7, 2008
Presentation Time: 4:30 PM
Room: Moscone Center SOUTH, Rooms 304-306-308
Directions: Howard Street entrance, turn left, up 2 flights of stairs to Esplanade level

About TargeGen, Inc.

TargeGen, Inc. is a privately held vascular biology-focused biopharmaceutical company based in San Diego, CA. TargeGen primarily develops small molecule kinase inhibitors that target vascular leakage (edema), vascular proliferation (angiogenesis) and inflammation. Edema, angiogenesis and inflammation are involved in the pathology of many major human diseases.

TargeGen initiated operations in 2002 and has raised capital from top tier venture capital sources. Current investors include VantagePoint Venture Partners, Forward Ventures, Enterprise Partners, Chicago Growth Partners, BB BIOTECH VENTURES, Innovis Investments, H&Q Capital Management, Pappas Ventures, CTI Life Sciences and other investors.

For additional information, contact:

TargeGen, Inc.
9380 Judicial Drive
San Diego, CA 92121
Tel 858-678-0760
Fax 858-678-0762
info@targegen.com
http://www.targegen.com